Dna-vaccine for application in patients with pancreatic cancer // 2636348
FIELD: biotechnology.SUBSTANCE: invention relates to an attenuated mutant Salmonella enterica Serovar Typhi Tu21a strain and a vaccine containing such a strain. The present strain contains, at least, one copy of a recombinant DNA molecule that contains a eukaryotic expression cassette encoding VEGF protein receptors, wherein the VEGF receptor protein is human VEGFR-2, which has an amino acid sequence as set forth in SEQ ID NO: 1 for use as a vaccine in immunotherapy of malignant tumours, where a single dose of the vaccine is 1×109 or less than 1×109 CFU.EFFECT: inventions allows to obtain necessary immunological and clinical responses at very low doses.16 cl, 12 dwg, 2 tbl, 7 ex
ethod for treatment of locally advanced breast cancer with tumour skin ulceration // 2626914
FIELD: medicine.SUBSTANCE: to treat locally advanced breast cancer with tumour skin ulceration, radiation therapy is performed in the mode of medium dose fractionation on the area of the mammary gland base and regional lymph drainage zone. In addition, prior to irradiation, a "Coletex-5-ftor" hydrogel tissue is applied to the tumour region for 5-7 days, 2-3 times daily. Prior to irradiation, a "Coletex-5-ftor" hydrogel tissue is applied to the area of skin tumour ulcers, where nitric acid silver is added as 0.2-2.0 wt %. At that, the marginal zones of skin tumour ulceration are treated with a hydrogel material on the basis of "Coletex-gel-DNA" sodium alginate, where betulin-containing birch bark extract is added as 0.1-1.5 wt %. After application of these hydrogels, a thermo-net is placed on top of them on the breast area, the net is cut out to overlap the ulcer area by 1.0-1.5 cm. Prior to radiotherapy, field markings in the ulcer area is carried out on the thermo-net.EFFECT: method ensures accelerated tumour ulcers healing, reduced drug load, reduced toxicity and a possibility of carrying out radiation therapy without interruption, reduced traumatization of tissues in the irradiation zone, and cessation of inflammatory processes.2 ex
ethod for complex treatment of infectious acute optical neuritis // 2623870
FIELD: medicine.SUBSTANCE: to treat infectious acute optical neuritis, retrobulbar infusions of dexamethasone and emoxipin are performed for 10 days via an irrigation system. Simultaneously, three immunomodulating preparations are used: 6 mg of polyoxidonium dissolved in 200.0 ml of physiological solution are injected intravenously every day; endonasal electrophoresis with 0.25% derinat solution at a current strength of 0.5-1 mA for 8 to 10 minutes; 2 ml of 12.5% of cycloferon are injected intramuscularly according to the scheme: the first 2 days - daily, the next 3 injections - every other day and the remaining 5 injections - every 3 days.EFFECT: use of the invention allows to restore the antibacterial and antiviral functions of the immune system, normalize the mechanisms of antioxidant protection, neuro-trophic activity, prevent the negative effects of GCS therapy, shorten the periods of inflammatory reaction arrest in the optic nerve and restore visual functions.2 ex
ethod of treating recurrent aphthous stomatitis // 2605687
FIELD: medicine.SUBSTANCE: invention relates to medicine, and namely to therapeutic dentistry and physiotherapy, and can be used for treating oral mucosa in patients, suffering from recurrent aphthous stomatitis. Antiseptic treatment of oral mucosa is made with 0.5 % hydrogen peroxide. 0.25 % solution of sodium deoxyribonucleat is applied on each inflammatory focus in form of applications with exposition for 10 minutes. Laser irradiation is exposed for 2 minutes for each aphtha. Laser radiation source is ALST-01 "OPTODAN". Radiation wavelength is 0.85-0.98 mcm. At first laser irradiation is carried out with laser radiation pulse with power of 2 W and pulse repetition frequency of laser radiation of 80-100 Hz, therapeutic course is 4 procedures. Then laser irradiation with laser radiation pulse power of 0.5 -1 W is performed, laser radiation pulse repetition frequency is 2,000-3,000 Hz, therapeutic course is 2 procedures.EFFECT: method provides reduced length of reduction of inflammation and aphtha epithelization, prolongs remission due to complex action, having immunomodulating, epithelizing and regenerative effect.1 cl, 1 ex

Sodium deoxyribonucleate suppositories, rectal and vaginal // 2601621
FIELD: pharmaceutics.SUBSTANCE: described is a pharmaceutical composition in form of a suppository, rectal or vaginal characterised by the fact that it contains as an active substance sodium salt of deoxyribonucleic acid and lipophilic base. Said base contains cocoa butter or cocoa butter alloys with paraffin or wax, or hydrogenated fat or vegetable and animal hydrogenated fats, or solid fat in the form of a mixture of lauric acid mono-, di- and triglycerides, or lanol, or alloys hydrogenated fats with wax or a solid paraffin at specified ratio. Also described is a method for preparing the composition.EFFECT: invention provides high stability during storage at maintaining sufficient bioavailability for effective action.3 cl, 3 tbl, 5 ex

ethod for gene therapy treatment of diabetic foot syndrome // 2599507
FIELD: medicine.SUBSTANCE: present group of inventions relates to medicine. Disclosed is the use of pCMV-VEGF plasmid splicing version 165 (Seq # 1) for treating diabetic foot syndrome and method for treating diabetic foot syndrome.EFFECT: presented group of inventions provides improved treatment results for diabetic foot by means of gene therapy.3 cl, 3 dwg, 4 tbl

Analgetic agent on the basis of plasmid dna coding hnp-1, or hnp-2, or hnp-3 (versions) // 2597789
FIELD: medicine.SUBSTANCE: invention relates to medicine and biotechnology and can be used for analgesia. Plasmid DNA for transient expression in cells of mammals is represented by scaffold, containing prokaryotic elements, origin of replication and reporter gene, and eukaryotic elements, strong promoter, a leader sequence mRNA, as well as regulatory sequences for the specified elements, from one site for cloning of a gene of interest and from one site for landing from one primer for analysis of composition of plasmid DNA, and polynucleotide presented by secretory sequence, the fragment coding human's alpha defensin HNP-1, or HNP-2, or HNP-3, kodonnally optimized for expression in mammalian cells, and the terminating sequence. Also a producer of plasmid DNA and analgesic agent based on it are disclosed.EFFECT: using inventions allows to extend the range of analgesic agents, to increase the duration and safety of analgesia.5 cl, 3 dwg, 3 ex

ethod of treating ascitic carcinoma // 2595864
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to oncology, and can be used for treating ascitic carcinoma. For this purpose tumour-bearing mice of CBA line weighing 20-35 g, carrying developed ascites, are parenterally administered cytostatic cyclophosphan for 0, 36, 72 hours each time in a dose of 100 mg/kg, and 18, 54, 90 hours after each injection of cyclophosphan, respectively. Also tumour-bearing mice are intraperitoneallly administered a DNA preparation, consisting of a composition of native human double-stranded DNA preparations in a dose of 3.0 mg and a mixture of native and cross-linked double-stranded DNA of salmon sperm at a ratio of 5:3 in a dose of 3 mg overall in an amount of 6.0 mg per injection, regardless of weight of tumour-mice.EFFECT: invention provides higher clinical effectiveness in ascitic carcinoma, which consists in prevention of occurrence of secondary ascites due to developed scheme of administration of cyclophosphan and DNA preparations.3 cl, 1 tbl, 7 dwg
ethod of treating chronic inflammatory periodontal diseases caused by yeast-like candida fungi depending on the condition of free-radical oxidation of oral fluid (versions) // 2593580
FIELD: medicine. SUBSTANCE: group of inventions refers to medicine, namely to therapeutic dentistry and laboratory diagnostics, and can be used for treating chronic inflammatory periodontal diseases caused by yeast-like Candida fungi. For this purpose there are presented two versions of the treatment method. One performs luminol-dependant chemiluminescence of oral fluid. One determines values of the maximum flash and total luminescence. In case of the first variant upon detection of increased state of free-radical oxidation of oral fluid antioxidant therapy is performed. For this purpose, there is conducted transverse electrophoresis of 0.25 % solution of sodium deoxyribonuclease on gingival mucosa at current intensity of 0.5-1 mA, then polarity is changed, starting with the positive pole, for 8-10 minutes; the course consists of 4 procedures made every second day. Mouth is also bathed in water solution of 0.25 % sodium deoxyribonuclease. Used is a toothpaste and mouthwash “Mexidol dent” during 8-12 days. In case of the second variant upon detection of decreased state of free-radical oxidation of oral fluid, pro-oxidant therapy is conducted. For this purpose, there is conducted transverse electrophoresis of 0.25 % solution of sodium deoxyribonuclease on gingival mucosa at current intensity of 0.5-1 mA, then polarity is changed, starting with the positive pole, for 8-10 minutes; the course consists of 4 procedures made every second day. Also, in the zone of gums projection, there is conducted magnet-IR laser therapy (MIRL-therapy) with the help of laser “Optodan” with a periodontal attachment, mode - 2-2,000 Hz by segments, 2 minutes per segment, not more than 12 minutes, the course of consists of 4 procedures performed every second day. Mouth is also bathed in water solution of 0.25 % sodium deoxyribonuclease. Used is a toothpaste and mouthwash “Parodontax” during 8-12 days. EFFECT: variants of the method provide a simplified and shorter duration of treatment due to adequate complex prolonged exposure of all links of the disease depending on the condition of free-radical oxidation of oral cavity. 2 cl, 2 ex

odulation of expression of transthyretin // 2592669
FIELD: biochemistry. SUBSTANCE: present invention relates to single-stranded modified oligonucleotides, capable of inhibiting expression of transthyretin in a cell. Said oligonucleotides have length from 15 to 30 linked nucleosides and can have a modified phosphorothioate bond, modified sugar and modified nucleobase, for example, 5-methylcytosine. Oligonucleotide according to present invention contains 5'-side segment linked to gap segment, which is linked with 3'-side segment. Present invention discloses a composition containing said oligonucleotide. Due to ability of said composition to inhibit expression of transthyretin, it is used for treating transthyretin amyloidosis, family amyloid polyneuropathy, family amyloid cardiomyopathy and senile systemic amyloidosis in humans. EFFECT: present invention widens range of agents for inhibiting expression of transthyretin in a cell and treating transthyretin amyloidosis in humans. 21 cl, 95 tbl, 24 ex

Pharmaceutical composition comprising microrna-100 and use thereof in modulating growth of blood vessels and endothelium inflammation // 2586531
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, specifically to the production of antagomirs to miRNA, and can be used in medicine for the treatment of vascular disease selected from the group consisting of peripheral vascular occlusive disease, coronary heart disease, cerebrovascular disease, vasculitis, atherosclerosis, vascular remodeling in response to injury or restenosis. Pharmaceutical composition with antagomir molecule miRNA-100 is prepared for the positive modulation of the growth of blood vessels, in this regard, for use in modulating the proliferation, tube formation and sprouting activities on endothelial cells or modulation of adhesion molecule expression by these cells.EFFECT: invention improves the effectiveness of angiogenic therapy.7 cl, 17 dwg, 9 ex

Phospholipid and cholesterol-containing ophthalmological system of medication delivery // 2572213
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to ophthalmology, and deals with system of ophthalmological medication delivery. This system includes means of delivery, which contains phospholipid or mixture of phospholipids, cholesterol, and therapeutic agent in specified weight ratios.EFFECT: system ensures effective delivery and prolongation of therapeutic agent action.16 cl, 3 dwg, 8 tbl, 8 ex

Dermatological pharmaceutical composition, suitable for oligonucleotides // 2570378
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to dermatology and can be used for the local treatment of inflammation. A pharmaceutical composition in the form of a water-in-oil-in-water emulsion or a water-in-oil emulsion with a disperse, internal, continuous water phase for local application contains: a lipophilic emulsifier, a thickening agent, saturated hydrocarbon, an inorganic and/or organic additive and antisense oligonucleotide, representing DNAzyme, with the dispersive, internal, continuous water phase containing the said antisense oligonucleotides.EFFECT: invention makes it possible to increase the stability of oligonucleotides in the composition, protect them from fermentative cleavage, and improve absorption.9 cl, 4 dwg, 2 ex
ethod of treating patients with localised scleroderma // 2564905
FIELD: medicine.SUBSTANCE: as a novel method of increasing the efficiency of treating localised scleroderma claimed is a method of treatment with deoxynate, which is characterised by high efficiency with the shorter treatment course duration in comparison with other therapeutic methods. The method of treating localised scleroderma consists in the additional application of deoxynate at the background of standard therapy in the form of a 0.5% injection solution with an active component of sodium deoxyribonucleate - sodium salt of partly depolymerised deoxyribonucleic acid, isolated from milts of the sturgeon, 0.005 g in a dose of 5 ml intramuscularly every second day with the course up to 10 days.EFFECT: method of treating patients with localised scleroderma makes it possible to obtain noticeable immunomodulating and therapeutic effect, favourable impact on the disease course, prolongation of remission, does not cause side effects and allergic reactions, results in the normalisation of the clinical pattern of the disease.3 ex

ethod of increasing stem cell pool in body // 2563235
FIELD: biotechnology.SUBSTANCE: intraperitoneal administration of hyaluronidase is carried out in a dose of 1000 CU/kg of body weight. And simultaneously hydrolyzate of ribonucleic acid is administered intraperitoneally, consisting of mono-, di-, tri-, tetra-, penta- and hexanucleotides pH 7.2 in a dose of 1 µg/kg body weight once a day for 2 days.EFFECT: increase in efficiency in increasing the pool of stem cells.1 ex, 1 tbl

ethod for lymphotropic administration of medicinal products in treating abdominal diseases // 2561832
FIELD: medicine.SUBSTANCE: medicinal products are administered through a catheter inserted according to Seldinger's technique. A spinous process of the twelfth thoracic spine is localised in a sitting patient with his/her back straightened; at 2.5-3.0 cm to the left from the spinous process, the skin and deeper tissues are anaesthetised with a local anaesthetic injected through a common injection needle. A Tuohy needle is then advanced along an upper edge of the rib to a body mid-line to reach a neural spine of the twelfth thoracic spine; it is passed over from above in the lateral direction; the needle is advanced into a retroperitoneal space to a point of thoracic duct formation; and Lidase 32 units dissolved in 0.25% novocaine 2 ml is injected through the inserted catheter. Then 5-10 minutes later, third- or fourth-generation cephalosporin 1000 mg dissolved in 0.25% novocaine 5 ml is injected 2 times a day for 5 days; Derinat solution 5 ml is injected every second day during 10 days; 2% novocaine is injected in a dose of 2 ml every 8 hours three times a day.EFFECT: method provides an optimum route of medicinal products administration to a pathologic lesion and ensures a prolonged lymphotropic therapy with effective anaesthesia, reducing the number of exudative-inflammatory complications.1 ex, 1 dwg
ethod of treating patients with chronic endometritis and tubal and peritoneal infertility factor // 2557957
FIELD: medicine.SUBSTANCE: method involves antibacterial, antimycotic, antiviral therapy taking into account sensitivity and recovered pathogenic flora and/or immune-enhancing therapy. From the 3rd day of the above therapy, local treatment involving the intrauterine insertion of a device for administering a complex of preparations and the prescribed hormone therapy is conducted. The device for administering the complex of preparations is presented by the Foley catheter, which is used to administer Miramistin 5 ml daily, Cefazoline or Ceftriaxone 4-6 minutes later, then Derinate 5 ml 4-6 minutes on even days, Longidaza 3 thousand units on odd days; the procedure is immediately followed by inserting a Miramistin tampon vaginally for 1-2 hours; one capsule of Polygynax is inserted vaginally for the night, whereas the hormone therapy is prescribed after the treatment.EFFECT: effective treatment of chronic endometritis and prevention of the tubal and peritoneal infertility.3 ex
ethod of treating radiation and interstitial cystitis // 2557949
FIELD: medicine.SUBSTANCE: method involves instilling the Colegel ADL gel preparation every second day from the 1st to 20th day, and then Colegel DNK L two times a week from the 21st to 56th day.EFFECT: invention enables relieving pain symptomatic, reducing the rate and length of recurrences in the patients.3 ex
ethod of improving functional-aesthetic results of plastic surgery of post-traumatic eyelid deformations // 2554810
FIELD: medicine.SUBSTANCE: to improve functional-aesthetic results of the plastic surgery of post-traumatic eyelid deformations, starting from 7-8 day from the moment of carrying out blepharoplasty of the post-traumatic cicatrical eyelid deformation, immediately after the removal of operational sutures, on the operated zone of the eyelid performed is a procedure of magnetic-photophoresis of a medical solution, made from 3000 ME of longidaze, 3 ml 25% solution of dimethylsulphoxide and 1 ml 0.25% solution of derinate, with 2 ml of the prepared solution being applied on an autodermal transplant and healthy skin surrounding it, with up to 1 cm indent from the wound edge, after 3-5 minutes a gauze pad, soaked with 2 ml of the remaining prepared solution, is applied on the processed surface of skin with the further 10 minute impact by a contact method by a travelling pulsed magnetic field of the apparatus "AMO-ATOS" with the frequency of pulse consecution of 5-10 Hz. Then, after the pad is removed, without the time interval, borders of the autodermal transplant and healthy skin closing are processed by infrared laser irradiation of a range of 0.89 mcm of the apparatus UZOR-2K with the frequency of the pulse repetition rate of 1500 Hz, in accordance with a contact labile method, 1 minute on each field, with carrying out 1 procedure daily for 10 days.EFFECT: improvement of the quality of skin transplant engraftment, absence of secondary eyelid deformations, and reduction of the post-operational treatment duration.1 tbl, 2 ex

ethod for eradication of initiating cancer stem cells // 2542410
FIELD: medicine.SUBSTANCE: cyclophosphane 200 mg/kg is injected into experimental animals carrying developed ascytis. Then, a DNA preparation is administered intraperitoneally every hour after administering cyclophosphane for 12 hours. The DNA preparation consists of a mixture of preparations of fragmented human DNA and cross-linked human DNA processed in nitrogen mustard.EFFECT: method provides the effective eradication of cancer stem cells by the synergism of the cytostatic and DNA preparation.3 cl, 5 dwg

ethod for preparing pharmaceutical composition for inducing angiogenesis in tissues, pharmaceutical composition prepared by this method, and method of treating individual's tissue and/or organ ischemia // 2542385
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biotechnology, specifically to compositions for inducing angiogenesis in tissues, and can be used in medicine. The method provides transforming the strain E. coli TOP10 by the pCMV-VEGF165 plasmid, culturing the strain in an environment acceptable for the biomass collection followed by separating the superhelical pCMV-VEGF165 plasmid that is followed by the pCMV-VEGF165 plasmid lyophilisation, which is conducted in the necessary presence in the lyophilised solution of a cryoprotectant, a pH stabiliser, an antioxidant and other substances enabling producing normal saline for injections with the pure plasmid concentration of 0.1 to 10 mg/ml and pH 7.0 to 9.0 and providing t the superhelical form of the pCMV-VEGF165 plasmid storage retention. The method of treating an individual's tissue and/or organ ischemia consists in administering an effective amount of the prepared pharmaceutical composition intramuscularly into the individual.EFFECT: invention enables preparing the therapeutically applicable pharmaceutical composition of the pCMV-VEGF165 plasmid DNA with preserving properties of the main substance at long-term storage at +2-+8°C.3 cl, 2 dwg, 4 tbl, 5 ex
ethod of treating cystitis // 2537031
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to methods of treating cystitis of various origins. Increasing the clinical effectiveness and reducing a probability of recurrences are ensured by administering therapeutically active and gel preparations possessing a high adhesion to urothelium walls. The method involves instilling sodium alginate in the form of Colegel gel containing the therapeutically active preparations dioxidine, lidocaine, deoxyribonucleate, sodium hyaluronate in a therapeutically effective amount with the instillation procedure suggested to be performed according to the schedule specified depending on the cystitis origin. If observing chronic bacterial recurrent cystitis, the following schedule is presented: instillations of Colegel-ADL from the 1st to 10th therapeutic day daily, instillations of Colegel-DNK-L from the 11th to 20th therapeutic day every second day, 2-month instillation of Colegel-Hyal once a week. Treating radiation and interstitial cystitis requires the following therapeutic schedule: instillations of Colegel-ADL from the 1st to 20th day, while Colegel-DNK-L and Colegel-Hyal are instilled once twice a week from the 21st to 56th day alternated every second day. The presented therapeutic schedules using the given therapeutically active preparations enabling relieving pain, reducing a rate and a length of recurrent cystitis.EFFECT: using these therapeutic schedules is high-efficient and safe.1 ex
ethod of quantitative evaluation of terminal nucleotides of g-chain of telomeric human rna by means of polymerase chain reaction and duplex-specific analysis, sets of synthetic oligonucleotide primers and probes for implementation of above said method // 2508407
FIELD: biotechnologies.SUBSTANCE: invention proposes a method involving stages of preliminary extraction of genomic RNA, extraction of a specific fraction of single-stranded G-overhanges of telomeric RNA and further amplification of their negative chain with duplex-specific analysis; besides, amplification stages include modification of 3'-ends of telomeric overhangs by means of terminal deoxynucleotidyl transferase and are implemented using a set of primers SEQ ID NO: 1-5. The duplex-specific analysis is based on hybridisation of minus chains of overhangs with a set of specific fluorescent marked probes SEQ ID NO: 6-11, which correspond to six possible versions of nucleotide endings of G-chain of telomeric human RNA. A buildup degree of probes in presence of a ferment of duplex-specific nuclease serves as a criterion of presence of the corresponding version of the nucleotide ending and a measure of its quantitative content. Obtained profiles of terminal nucleotides of G-chain of telomeric RNA serve as proliferative markers pointing at an activation degree of cell fission and determining time duration of a cellular cycle.EFFECT: invention is a new kind of RNA diagnostics, intended for detection of changes of nucleotide endings of RNA of telomeric areas of chromosomes, which occur in the cellular cycle process, and can be used in medicine for diagnostics and treatment of cancer, in immunology, transplantology, cosmetology, dermatology, gerontology, cellular biotechnology and other areas involved in evaluation of a proliferative state of a cell and methods of its directed control.15 cl, 9 dwg, 8 tbl, 5 ex

Injection composition of polydeoxyribonucleotides for treating osteoarticular diseases // 2508115
FIELD: medicine, pharmaceutics.SUBSTANCE: what is described is a pharmaceutical composition of polydeoxyribonucleotides extracted from natural sources. The composition contains a fraction of polydeoxyribonucleotides extracted from fish sperm cells, wherein the above polydeoxyribonucleotides possess polymer chains of various molecular weights 70 kDa to 240 kDa.EFFECT: composition is applicable as a therapeutic agent for treating osteoarticular diseases, especially osteoarthritis by an intra-articular injection to provide a required joint fluid viscosity.8 cl, 13 dwg

Complement-binding aptamers and c5 agents applicable for treating ocular disorders // 2477137
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely ophthalmology, and may be used for treating, stabilising and/or preventing macular degeneration. The therapy involves introduction of a therapeutically effective amount of the C5 agent in a combination with a VEGF agent in an individual in need thereof. The C5 agent is bound with C5 complement and has the sequence SEQ ID N0:4 or SEQ ID N0:67.EFFECT: invention provides an additive or synergetic effect ensured by the combination that leads to improved visual acuity especially in the patients suffering wet age-related macular degeneration (AMD) as compared with the VEGF monotherapy.67 dwg, 8 ex
ethod of treating postoperative corneal oedema in age-related cataract surgery // 2476194
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely ophthalmology, and may be used for treating postoperative corneal oedemas in age-related cataract surgery. For this purpose, 0.25% derinate is instilled for 3 times for 1 minute from the first postoperative day. Immediately after the last instillation, the cornea is exposed to a travelling pulse magnetic field generated by the AMO-ATOS apparatus with its radiation head placed at 3 mm from the external cornea. It is combined with the laser light exposure. A laser beam generated by the LAST-01 apparatus is directed through an axial hole in the field radiation head. Radiator frequency is 5-10 Hz; diaphragm position is 4; exposure time is 5 min; the therapeutic course is 2-3 sessions.EFFECT: method improved the surgical outcomes and reduces the length of treating the gerontological patients suffering the declared pathology ensured by reducing the length of recovering the normal anatomic-physiological and optical corneal state, reducing the rate of chronic bullous keratopathy, recovering developed mechanisms causing energy and metabolic cell reserves.1 tbl, 2 ex
ethod of treating breast cancer // 2471520
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to oncology, and may be applied in treating breast cancer. Breast is resected. Coletex-Mex textile tissue is applied for 4-7 days in 7-10 postoperative days on the postoperative scar and remained breast tissues, and changed 2 times a day. For the following 4-7 days, Coletex-D hydrogel tissue is applied and coated with Coletex-SMT textile tissue in the same regiment. The applications for 8-10 hours a day are combined with radiation teletherapy to SRD 20 Gy - 25 Gy. The radiation teletherapy is combined with the applications of Coletex gel DNA hydrogel coated with Coletex-Mex textile tissues from above changed twice a day. The radiation teletherapy is followed by the application of Coletex-SMT tissue and Coletex-Mex tissues changed every 12 hours to complete rehabilitation.EFFECT: method provides fast healing of the postoperative wound, reduced length of the beginning of radiation and chemotherapy, minimal rate of complications and side reactions thereby improving patient's quality of life.1 ex

Treatment and prevention of neurodgenerative diseases with use of gene therapy // 2471487
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely neurology, and concerns treatment and prevention of neurodegenerative diseases, particularly Alzheimer's disease with the use of gene therapy. That is ensured by the introduction of a composition containing one or more nucleic acids inducing cell immune response. The nucleic acids to be introduced code one or more cytokines specified in a group consisting of IL-4 (interleukine-4), IL-10 (interleukine-10) and TGF-β (transforming growth factor beta).EFFECT: method provides reduced cerebral accumulations of amyloid formations.16 cl, 7 ex, 7 dwg
ethod of treating cancer of rectum // 2434591
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for treatment of cancer of rectum. For this purpose during operation in presacral space till its complete filling-in introduced is medication - "hydrogel napkins with 5-fluoruracyl and sodium alginate "Coletex -5-ftur" with addition of 50 mg of carboplatin. Two drainages of different diameter are installed into presacral space. After that, peritonisation with uninterrupted suture is carried out tightly. On 5-6 day after operation hydrogel "Coletex-gel-DNA" is introduced through drainages into presacral space until it is completely filled.EFFECT: method ensures reduction of frequency of local recurrences and metastases after cancer of rectum surgery due to efficient intraoperative local chemical therapy in combination with reparative therapy after operation.1 ex

Immunostimulating combination for prevention and treatment of hepatitis c // 2431499
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, and concerns an immunostimulating combination for prevention and treatment of hepatitis C. Substance of the invention consists in creation of the immunostimulating combination containing poly I - poly C [poly (I:C)] used as an Toll-like receptor TLR3 agonist, CD40 agonist, a polypeptide which includes protein NS3 of hepatitis C virus, or a fragment of said protein exhibiting ability to CD8+ and CD4+ response induction, and the agonist is chosen from anti-CD40- antibodies, CD40L (natural ligand CD40) and their fragments which keep their ability to bind with CD40. The invention also includes application of said combination for preparing a drug, a pharmaceutical composition, a vaccine, a kit for introduction of the combination and a method for inducing an immune response on hepatitis C virus.EFFECT: higher clinical effectiveness and lower toxicity.24 cl, 5 ex, 1 tbl, 5 dwg
Derinat suppositories to be used in medical practice // 2429854
FIELD: medicine.SUBSTANCE: for treating urogenital clamidiosis, cytomegalovirus, herpes simplex, Helicobacter pylori, polyethylene oxide 1500 and polyethylene oxide 400 are melted in the ratio 9:1; the liquid melt is added with a design amount of the preservative sodium chloride; further a design amount of sodium deoxyribonucleate is added in mixing. A melted paste is mould to prepare Derinat suppositories of 1.3-2.5 g.EFFECT: prepared suppositories provide high bioavailability and prolonged action of the active agent.3 cl, 7 tbl, 2 ex

Treatment of cns disorders // 2426544
FIELD: medicine.SUBSTANCE: invention relates to field of medicine. Claimed invention relates to method and composition for treatment of central nervous system (CNS) disorder by intranasal application of compounds, which induce RNA interference. Composition by the invention contains molecules of short interfering nucleic acids (siPHK). Disorder is selected from dementia, Alzheimer's disease, Huntington's disease and/or Parkinson's disease, as well as congenital diseases associated with mutations in CNS genes. According to the invention method includes introduction to patient in case of necessity of efficient amount of one or more siPHK in accordance with the invention.EFFECT: invention ensures suppression of expression of target genes, connected with changed CNS states.20 cl, 4 ex, 8 dwg
edication for treatment of psoriasis // 2424811
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, in particular for treatment of psoriasis. Medication for treatment of psoriasis, which contains solution of phospholipids in 70% ethyl alcohol and water solution of sodium deoxyribonucleate, components being taken in specified ratio.EFFECT: medication is efficient for treatment of psoriasis.4 ex

Treatment of intestinal diseases // 2418594
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to gastroenterology, and can be used for treatment of intestinal diseases. For this purpose applied is intrarectal introduction of compounds which cause RNA interference. In addition, claimed are RNKi compounds with specified nucleotide sequence, causing RNA-interference and intended for intrarectal introduction, whose target is interleukin-12 gene. Claimed compounds can also be used for treatment of intestinal diseases.EFFECT: inventions ensure efficient disease treatment due to efficient reaching and impact in action targets.43 cl, 1 tbl, 5 ex, 9 dwg

Anti-sense oligonucleotides for treating allergy and proliferation of neoplastic cells // 2416412
FIELD: medicine.SUBSTANCE: invention relates to field of medicine and deals with anti-sense oligonucleotides for treatment and/or prevention of, at least, one of the following diseases: asthma, hypereosinophilia. Essence of the invention includes oligonucleotides aimed against sequences of nucleic acids, coding receptor, selected from group, which consists of receptor CCR3 and common subunit of receptors IL-3, IL-5 and GM-CSF with sequences SEQ ID NO:1 and SEQ ID NO:14.EFFECT: reduction of toxicity in comparison with hormonal medications.39 cl, 8 ex, 11 tbl, 21 dwg

Vaccine composition containing immune-stimulating oligodeoxynycleotides // 2413520
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biotechnology and medicine. Offered is a vaccine composition containing immune-stimulating oligodeoxynucleic acid containing deoxyinosine residues (I - ODN) and antigens.EFFECT: vaccine compositions elicit a more effective immune response in comparison with CpG sequence ODN and reduce induction of adverse reactions.13 cl, 9 dwg, 6 ex
Cosmetic preparation and method for making thereof // 2407509
FIELD: medicine.SUBSTANCE: invention refers to a cosmetic preparation used for skin elasticity improvement and containing an active ingredient and a carrier where the active ingredient contains a complex which includes a telomere DNA sequence and a related peptide having a nuclear localisation signal, and which is capable to penetrate through a plasma cell membrane.EFFECT: production of the preparation for skin elasticity improvement.5 cl, 1 ex
ethod of treating locally advanced oropharyngeal cancer // 2401139
FIELD: medicine.SUBSTANCE: method involves polychemotherapy followed by radiation therapy (RT) with underlying plant-based mouth rinsing and oral administration of Colegel with Derinat and Lidocaine 3 times a day and more often. The polychemotherapy is performed by no more than 2 courses with the radiation started not earlier than in 10-15 days after the polychemotherapy to total basic dose 66-70 Gy and with peripheral blood of an exposed patient analysed for lymphocyte count once in 10 days and more often. If lymphocyte count is 1.2×109/l or less, the following RT sessions are carried out with underlying additional intensive local and system therapy, or the therapy is interrupted for the hemostimulation therapy.EFFECT: use of the invention allows preventing severity gain in a radiation involvement of oropharyngeal mucosa due to well-timed intensification of local and system therapy, performing a radical RT course and improving clinical effectiveness.2 cl, 2 ex
ethod of treating moderately active and replicative chronic viral hepatitis type c of 1-genotype // 2398582
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to hepatology, and can be used in treating moderately active and replicative chronic viral hepatitis type C of 1-genotype. That is ensured by parenteral introduction of interferon-α in dosage 3 million IU and interferon-γ in dosage 500 thousand IU every second day and daily double oral introduction of Ribamidyl in dosage 15 mg per kg of body weight. Every 3 months, the interferon therapy is recessed for 10-12 days. Over this period, the preparation Derinat is administered daily. The total therapeutic course is 9 months and 20-24 days, and combined introduction of interferon-γ and interferon-α are performed within the first 6 months. For the next 3 months, interferon-a is administered. Ribamidyl is required for the whole therapeutic course.EFFECT: higher clinical effectiveness and prevention of interferon-resistance development.2 tbl, 4 ex

Biologically active food supplement "biosinol", which possesses gastroprotective activity // 2397775
FIELD: medicine.SUBSTANCE: invention relates to pharmacology and pharmaceutical industry, in particular to gastroprotective preparation. Application of biologically active supplement to food "Biosinol" as gastroprotective preparation.EFFECT: said preparation efficiently increases mucous barrier function and resistance of mucous membrane to development of stress ulcers and iatrogenic damage to stomach resulting from intake of non-steroidal anti-inflammatory drugs.3 tbl
ethod of obtaining complex medication for prevention and treatment of metabolism pathology and malfunctions of immune system in animals // 2395278
FIELD: medicine.SUBSTANCE: invention relates to veterinary, in particular to development of complex medications for prevention and treatment of malfunctions of metabolic and immune processes in animals. Method of obtaining complex medication for prevention and treatment of malfunctions metabolic and immune system includes mixing of succinic acid, novocaine, immunostimulant, dissolving of obtained medication in distillated water and sterilising by autoclaving. As immunostimmulant applied is sodium nucleinate or derinate with the following component ratio, wt %: succinic acid 1.5; sodium nucleinate or derinate 2.0; novocaine 0.25; distillated water - the remaining part.EFFECT: invention insures increasing of medication efficiency.4 tbl, 2 ex

Oligonucleotide polymeric prodrugs // 2394041
FIELD: medicine.SUBSTANCE: invention refers to polymer conjugates of formula (I) comprising nucleotide or oligonucleotide residue, which can be applied for treatment of cancer and methods for their obtaining. where R1 and R2 independently represent H or polyalkylenoxyde, not necessarily having capping group selected from OH, NH2, SH, CO2N, C1-6 alkyls, compounds of formula (II) X2-(L2)n-(L1)o- and the formula (III) -(L4)p-(L3)m-X3, and when (o+n)≥2 each of n and o is a positive integer, each p and m are equal to zero, and R2 represents H, and when (p+m)≥2 each p and m is a positive integer, each n and o are equal to zero and R1 represents H; X1, X2, X3 are independently selected from a single-stranded or double-stranded oligonucleotide residue; L1 and L4 independently represent released link fragments; L2 and L3 are independently selected from bifunctional spacer groups.EFFECT: developing of new nucleotide conjugates with antitumor activity.21 cl, 25 ex, 7 tbl, 12 dwg
Way preventing postoperative adhesions formation // 2363476
FIELD: medicine.SUBSTANCE: invention concerns medicine, namely, to abdominal surgery, and can be used for prevention of formation of postoperative adhesions of serous cavities. For this purpose deserosed and-or the inflamed sites of organs and a cavity wall are covered with an admixture of sterile gel "Lintexum-Mesogel" and derinate during an operative measure on organs of serous cavities. Derinate volume makes from 1% to 25% from all volume of the admixture. The way allows preventing development of adherent process in abdominal cavity in the postoperative period without additional administration of other medicinal preparations during this period at the expense of local prolonged immunopotentiation provision and consolidation prevention of deserosed surfaces.EFFECT: prevention of development of adherent process in abdominal cavity in the postoperative period without additional administration of other medicinal preparations during this period at the expense of local prolonged immunopotentiation provision and consolidation prevention of deserosed surfaces.2 tbl, 1 ex

Bronchial asthma treatment mode // 2360698
FIELD: medicine.SUBSTANCE: treatment of the patients suffering from bronchial asthma involves basic therapy combined with Rusam. Additionally, sodium nucleinate is prescribed in a dose 0.5 g daily twice a day within 20 days and capsulated Hypoxene dosed 0.1-0.2 g a day, daily within 7 days.EFFECT: scheduled introduction of such drug combination allows improving clinical effectiveness, including due to selective effect on the certain links of immune system and desensitisation through induction of specific immune response on introduction of Rusam, its enchancement with sodium nucleinate and elimination of hypoxic conditions.1 tbl, 1 ex

Aptamers on basis of dna for human cathepsine g // 2360000
FIELD: medicine.SUBSTANCE: invention concerns identification of non-peptide inhibitors of cathepsine G. The given substances immediately inhibit biological functions of the target protein. The cathepsine G-inhibiting aptamers consist of linear DNA-sequences or polynucleotide sequences which have length of a chain at least of 60 nucleotides and not subjected to effective pairing of the bases.EFFECT: offered aptamers are characterised by high selectivity and can be used at treatment and preventive maintenance of inflammatory processes and procoagulant conditions.7 cl, 3 dwg, 1 tbl

Agent and therapy of exudative otitis media // 2358743
FIELD: medicine.SUBSTANCE: therapy of exudative otitis media is ensured by introduction of antibacterial, mucolytic, vasoconstrictive and proteolytic agents. It is combined with transtympanic introduction of 1.5% sodium deoxyribonucleate solution (Derinate) dosed 0.5 ml every second day into tympanic cavity. The therapeutic course is 4 injections of Derinate.EFFECT: higher clinical effectiveness, reduced time of auditory perception threshold restoration.3 tbl, 2 ex, 1 dwg
ethod of antistress macular retina protection in cataract surgery in complicated diabetes patients // 2356519
FIELD: medicine.SUBSTANCE: invention refers to ophthalmology and can be used for antistress macular retina protection in cataract surgery in diabetes patients before, during and after operation. One day prior to operation the patient is exposed to single 30-minute "ТЭС" therapy session with using an apparatus Transair-01 at bipolar rectangular pulse current of fixed frequency and duration. After the session and the operation day 0.25% Derinate solution is instilled 2 drops per each nostril. It is combined with intravenous droplet introduction of 1.5% Reamberine solution 200 ml. From first postoperative day, 20% Levocarnitine solution is prescribed 3 times a day in dose 1 ml or 1 tablet combined with 0.25% Derinate solution instilled 3 times a day in dose 2 drops per each nostril at the same frequency rate. Combined postoperative Levocarnitine and Derinate therapy lasts from the character of reciprocal morphological macular retina reaction on surgical stress. If macular retina volume gains within the first 3-5 postoperative 10% of average norm, treatment length is 10 days, and 30 days, if 10% are exceeded.EFFECT: improved antistress macular retina protection by replacing deficiency of plastic protein substrates in photoreceptors.3 ex, 1 tbl
ethod for treatment of locally advanced oropharyngeal cancer // 2347591
FIELD: medicine; oncology.SUBSTANCE: induction chemotherapy is carried out by introduction of cisplatin and 5-fluorouracyl. Then chemoradiation therapy is performed with introduction of carboplatin once a week. Thirty-forty minutes before performance of radiation therapy, "Coletex-gel-DNA-L" is introduced into patient's oral cavity. Introduction of "Coletex-gel-DNA-L" is continued every 3-4 hours during radiation therapy and 2-3 times per day for 1 month on its completion. Patient's radiation is carried out daily until total focal dose makes 72-74 Gy with application of conformal radiation therapy on the basis of volume three-dimensional planning.EFFECT: maximum safe radiation therapy with significant reduction of local toxic reaction of organism.2 ex
Treatment method for chronic endometritis // 2342173
FIELD: medicine, gynecology.SUBSTANCE: vulva sanitation is conducted. Then ultrasound exposure of vagina is conducted during 60 seconds, through intermediate antiseptic solution infused into the cavity. Whereupon 100 IU poludane dissolved in 5 ml sterile injection solution, is introduced into uterine cavity. At the same time ultrasound exposure of endometrium is conducted during 60 seconds. The low-frequency ultrasound with 26.5 kHz frequency and 50 mcm amplitude is applied in continuous mode. Treatment procedures are effected every morning at first phase of menstrual cycle, 1.5 to 2 hours after the meal. The course includes 5 procedures.EFFECT: increased therapy efficiency due to complications reduction, steady treatment result, curing period shortening, and medicament load easing.1 ex

Interferon inductor suppositories // 2328272
FIELD: medicine; pharmacology.SUBSTANCE: proposed suppository along with consistent base (lipophilic, hydrophilic or diphilic) and stabiliser selected from chlorhexidine bigluconate, nypagine and sodium carboxymethyl cellulose as natural endogenous interferon inductor, is supplied with sodium salt complex of alpha-helical and double-helical RNA from killer yeast Saccharomyces cerevisiae. Quantitative amount of specified ingredients per suppository of mass 1.0 g is: sodium salt complex of alpha-helical and double-helical RNA from killer yeast Saccharomyces cerevisiae - 50-150 mcg; stabiliser - 10-30 mcg; additives - others.EFFECT: extended range of therapeutic antiviral agents and reduced toxicity with maintained efficiency.6 cl, 4 ex, 3 tbl